CAR T therapy shows durable responses in large B-cell lymphoma

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?

January 09, 2026

Vol.52 No.1

By Ofer Sharon, Michal Harel and Yehonatan Elon

Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

December 19, 2025

Vol.51 No.46

Drugs & Targets

EC approval of Minjuvi in relapsed or refractory follicular lymphoma

The European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grade 1-3a) after at least one line of systemic therapy.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

Researchers have discovered a previously unknown pathway that could explain why androgens remain and prostate cancer progresses despite treatment with androgen deprivation therapy.

December 12, 2025

Vol.51 No.45

In Brief

Mark Veich named chief organizational advancement officer of Parker Institute for Cancer Immunotherapy

Mark Veich was namedchief organizational advancement officer at the Parker Institute for Cancer Immunotherapy.

December 05, 2025

Vol.51 No.44

In Brief

Vincent Wu named Casper Wistar Fellow at Vaccine & Immunotherapy Center

Vincent Wu was named a Caspar Wistar Fellow at the Wistar Institute’s Vaccine & Immunotherapy Center.

December 05, 2025

Vol.51 No.44

CAR T therapy shows durable responses in large B-cell lymphoma

YOU MAY BE INTERESTED IN

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

EC approval of Minjuvi in relapsed or refractory follicular lymphoma

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

Mark Veich named chief organizational advancement officer of Parker Institute for Cancer Immunotherapy

Vincent Wu named Casper Wistar Fellow at Vaccine & Immunotherapy Center

Renew today!

Subscriber content

Never miss an issue!

Login